A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

MC #22-03

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

NCT #
NCT05277051
Condition(s)
Breast, Clear Cell Renal Cell, Colorectal, Endometrial, Gastric, head and neck squamous cell carcinoma, Non-Small Cell Lung, Ovarian Epithelial
Molecular Target(s)
PVRIG
Drug Classification(s)
Immunotherapy, Monoclonal Antibody, Targeted Therapy
Agents(s)
GSK4381562
Phase(s)
I

Mechanism of Action

GSK4381562A is a PVRIG antibody to block this receptor thus preventing a signal that can inhibit the function of T cells in the immune system.

Purpose

  • How much of the study agent 1 can be given alone, or in combination with Dostarlimab, or in combination with Dostarlimab and study agent 2 with an acceptable level of side effects
  • The effects of the study agent 1 when given alone, or in combination with Dostarlimab, or in combination with Dostarlimab and study agent 2 (good and bad)
  •  How much of the study agent is absorbed into the blood and how fast it is removed
  •  If research tests can be used in the future to predict who will benefit from study agent 1 when given alone, or in combination with Dostarlimab, or in combination with Dostarlimab and study agent 2.

Location

MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.